Emerging therapies in non-small-cell lung cancer.

[1]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  P. Thall,et al.  Phase I study of farnesyl tranferase inhibitors (FTI) SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety , 2000 .

[3]  M. Ranson,et al.  Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[4]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[5]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Roszkowski,et al.  A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). , 2000, Lung cancer.

[7]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Carbone,et al.  Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Gregor,et al.  Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[11]  E K Rowinsky,et al.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Georgoulias,et al.  Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial , 1999 .

[13]  D. Johnson,et al.  Treatment strategies for metastatic non small-cell lung cancer. , 1999, Clinical lung cancer.

[14]  G. Scagliotti,et al.  Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Gandara,et al.  Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. , 1999, Seminars in oncology.

[16]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[17]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Rosen,et al.  Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Carmichael,et al.  24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC) , 1997 .

[20]  J. Rigas.  SINGLE-AGENT DOCETAXEL IN PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG CANCER , 1997 .

[21]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[22]  S Lippman,et al.  Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Angeletti,et al.  Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. , 1995, European journal of cancer.

[24]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  G Cartei,et al.  Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. , 1993, Journal of the National Cancer Institute.

[26]  R. Figlin,et al.  Supportive care versus supportive care and combination chemotherapy in metastatic non‐small cell lung cancer. Does chemotherapy make a difference? , 1989, Cancer.

[27]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Todd.  Cancer of the Lung , 1975, British Journal of Cancer.

[29]  J A TAIANA,et al.  [Cancer of the lung]. , 1952, The Journal of the International College of Surgeons.